Search Results

The Philips IntelliSite Pathology Solution (PIPS) 5.1 is an automated digital slide creation, viewing, and management system. The PIPS 5.1 is intended for in vitro diagnostic use as an aid to the pathologist to review and interpret digital images of surgical pathology slides prepared from formalin-fixed paraffin embedded (FFPE) tissue. The PIPS 5.1 is not intended for use with frozen section, cytology, or non-FFPE hematopathology specimens.

The PIPS 5.1 comprises the Imagement System (IMS) 4.2, Ultra Fast Scanner (UFS), Pathology Scanner SG20. Pathology Scanner SG60, Pathology Scanner SG300 and Philips PP27QHD display, a Beacon C411W display or a Barco MDCC-4430 display. The PIPS 5.1 is for creation and viewing of digital images of scanned glass slides that would otherwise be appropriate for manual visualization by conventional light microscopy. It is the responsibility of a qualified pathologist to employ appropriate procedures and safeguards to assure the validity of the interpretation of images obtained using PIPS 5.1.

The Philips IntelliSite Pathology Solution (PIPS) 5.1 is an automated digital slide creation, viewing, and management system. PIPS 5.1 consists of two subsystems and a display component:

• 1. A scanner in any combination of the following scanner models
  • . Ultra Fast Scanner (UFS)
  • Pathology Scanner SG with different versions for varying slide capacity . Pathology Scanner SG20, Pathology Scanner SG60, Pathology Scanner SG300
• 2. Image Management System (IMS) 4.2
• 3. Clinical display
  • PP27QHD or C411W or MDCC-4430 .

PIPS 5.1 is for creation and viewing of digital images of scanned glass slides that would otherwise be appropriate for manual visualization by conventional light microscopy. The PIPS does not include any automated image analysis applications that would constitute computer aided detection or diagnosis. The pathologists only view the scanned images and utilize the image review manipulation software in the PIPS 5.1.

This document is a 510(k) summary for the Philips IntelliSite Pathology Solution (PIPS) 5.1. It describes the device, its intended use, and compares it to a legally marketed predicate device (also PIPS 5.1, K242848). The key change in the subject device is the introduction of a new clinical display, Barco MDCC-4430.

Here's the breakdown of the acceptance criteria and study information:

1. Table of Acceptance Criteria and Reported Device Performance

The submission focuses on demonstrating substantial equivalence of the new display (Barco MDCC-4430) to the predicate's display (Philips PP27QHD). The acceptance criteria are largely derived from the FDA's "Technical Performance Assessment of Digital Pathology Whole Slide Imaging Devices" (TPA Guidance) and compliance with international consensus standards. The performance is reported as successful verification showing equivalence.

2. Sample Size Used for the Test Set and Data Provenance

The document does not explicitly state a "sample size" in terms of cases or images for the non-clinical performance tests. The tests were performed on "the display of the proposed device" to verify its technological characteristics. This implies testing on representative units of the Barco MDCC-4430 display.

The data provenance is not specified in terms of country of origin or retrospective/prospective, as the tests were bench testing (laboratory-based performance evaluation of the display hardware) rather than clinical studies with patient data.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and their Qualifications

This information is not applicable to this submission. The tests performed were technical performance evaluations of hardware (the display), not clinical evaluations requiring expert interpretation of medical images. Ground truth for these technical tests would be established by objective measurements against specified technical standards and parameters.

4. Adjudication Method for the Test Set

This information is not applicable to this submission. As the tests were technical performance evaluations of hardware, there would not be an adjudication process involving multiple human observers interpreting results in the same way there would be for a clinical trial.

5. If a Multi Reader Multi Case (MRMC) Comparative Effectiveness Study was done

No, a Multi Reader Multi Case (MRMC) comparative effectiveness study was not done.

The submission explicitly states: "The proposed device with the new display did not require clinical performance data since substantial equivalence to the currently marketed predicate device was demonstrated with the following attributes: Intended Use / Indications for Use, Technological characteristics, Non-clinical performance testing, and Safety and effectiveness."

Therefore, there is no effect size reported for human readers with and without AI assistance, as AI functionality for diagnostic interpretation is not the subject of this 510(k) (the PIPS 5.1 "does not include any automated image analysis applications that would constitute computer aided detection or diagnosis").

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was done

This information is not applicable. The PIPS 5.1 is a digital slide creation, viewing, and management system, not an AI algorithm for diagnostic interpretation. The focus of this 510(k) is the display component. The device itself is designed for human-in-the-loop use by a pathologist.

7. The Type of Ground Truth Used

For the non-clinical performance data, the "ground truth" was based on:

• International and FDA-recognized consensus standards: This includes IEC 60601-1, IEC 60601-1-6, IEC 62471, and ISO 14971.
• TPA Guidance: The "Technical Performance Assessment of Digital Pathology Whole Slide Imaging Devices" guidance document, which specifies technical parameters for displays.
• Predicate device characteristics: Demonstrating that the new display's performance matches or is equivalent to the legally marketed predicate device's display across various technical parameters.

In essence, the ground truth was established by engineering specifications, technical performance targets, and regulatory standards for display devices.

8. The Sample Size for the Training Set

This information is not applicable. The PIPS 5.1, as described, is a system for digital pathology, not an AI algorithm that requires a training set of data. The 510(k) specifically mentions: "The PIPS does not include any automated image analysis applications that would constitute computer aided detection or diagnosis." Therefore, there is no AI training set.

9. How the Ground Truth for the Training Set Was Established

This information is not applicable, as there is no AI training set.

Ask a specific question about this device

The Philips IntelliSite Pathology Solution (PIPS) 5.1 is an automated digital slide creation, viewing, and management system. The PIPS 5.1 is intended for in vitro diagnostic use as an aid to the pathologist to review and interpret digital images of surgical pathology slides prepared from formalin-fixed paraffin embedded (FFPE) tissue. The PIPS 5.1 is not intended for use with frozen section, cytology, or non-FFPE hematopathology specimens.

The PIPS 5.1 comprises the Imagement System (IMS) 4.2, Ultra-Fast Scanner (UFS), Pathology Scanner SG20, Pathology Scanner SG60, Pathology Scanner SG300 and Philips PP270HD display or a Beacon C411W display. The PIPS 5.1 is for creation and viewing of digital images of scanned glass slides that would otherwise be appropriate for manual visualization by conventional light microscopy. It is the responsibility of a qualified pathologist to employ appropriate procedures and safeguards to assure the validity of the interpretation of images obtained using PIPS 5.1.

The Philips IntelliSite Pathology Solution (PIPS) 5.1 is an automated digital slide creation, viewing, and management system. PIPS 5.1 consists of two subsystems and a display component:

• 1. A scanner in any combination of the following scanner models
  • . Ultra Fast Scanner (UFS)
  • . Pathology Scanner SG with different versions for varying slide capacity Pathology Scanner SG20. Pathology Scanner SG60. Pathology Scanner SG300
• 2. Image Management System (IMS) 4.2
• 3. Clinical display
  • PP27QHD or C411W

PIPS is for creation and viewing of digital images of scanned glass slides that would otherwise be appropriate for manual visualization by conventional light microscopy. The PIPS does not include any automated image analysis applications that would constitute computer aided detection or diagnosis. The pathologists only view the scanned images and utilize the image review manipulation software in the PIPS.

This document focuses on the Philips IntelliSite Pathology Solution 5.1 (PIPS 5.1) and its substantial equivalence to a predicate device, primarily due to the introduction of a new clinical display. This is a 510(k) submission, meaning it aims to demonstrate that the new device is as safe and effective as a legally marketed predicate device, rather than proving de novo effectiveness. Therefore, the study described is a non-clinical performance study to demonstrate equivalence of the new display, not a clinical effectiveness study.

Based on the provided text, a detailed breakdown of acceptance criteria and the proving study is as follows:

1. Table of Acceptance Criteria and Reported Device Performance

The document states that the evaluation was performed following the FDA's Guidance for Industry and FDA Staff entitled, "Technical Performance Assessment of Digital Pathology Whole Slide Imaging Devices" (TPA Guidance), dated April 20, 2016. The acceptance criteria are essentially defined by compliance with the tests outlined in this guidance and relevant international standards.

Reported Device Performance Summary: The non-clinical performance testing of the new display (Beacon C411W) showed that the proposed device has similar technological characteristics compared to the predicate device (using the PP27QHD display) following the TPA Guidance. It is also in compliance with the aforementioned international and FDA-recognized consensus standards. The verification and validation of existing safety, user, and system integration requirements showed that the proposed PIPS 5.1 with the new clinical display is safe and effective.

2. Sample Size Used for the Test Set and Data Provenance

• Sample Size: The document does not specify a "sample size" in terms of patient cases or images for testing the display. The testing performed was bench testing ("Verification for the new display," "non-clinical performance data"). This implies that the tests were conducted on the display unit itself, measuring its physical and optical properties, and its integration with the system components, rather than on a dataset of patient images reviewed by observers.
• Data Provenance: Not applicable in the context of a display characteristic validation study. The study focused on the performance of the hardware (the new display).

3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications

Not applicable. This was a technical, non-clinical validation of a display unit's characteristics against engineering specifications and regulatory guidance, not a study requiring expert clinical read-outs or ground truth establishment from patient data.

4. Adjudication Method for the Test Set

Not applicable. This was a technical, non-clinical validation.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done

• No, an MRMC comparative effectiveness study was NOT done. The document explicitly states: "The proposed device with the new display did not require clinical performance data since substantial equivalence to the currently marketed predicate device was demonstrated with the following attributes: Intended Use / Indications for Use, Technological characteristics, Non-clinical performance testing, and Safety and effectiveness."
• The purpose of this submission was to demonstrate substantial equivalence for a minor hardware change (new display), not to show an improvement in human reader performance with AI assistance. The PIPS system itself does not include "any automated image analysis applications that would constitute computer aided detection or diagnosis." It is a whole slide imaging system for viewing and managing digital slides.

6. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done

• Not applicable. The PIPS 5.1 is a system for creating, viewing, and managing digital slides for human pathologist review. It is not an AI algorithm that produces a diagnostic output on its own. The "standalone" performance here refers to the display's technical specifications.

7. The Type of Ground Truth Used

• For the non-clinical performance data, the "ground truth" was established by engineering specifications, international consensus standards (e.g., IEC, ISO), and the FDA's TPA Guidance. The aim was to ensure the new display performed equivalently to the predicate's approved display and met relevant technical requirements.

8. The Sample Size for the Training Set

Not applicable. This was a non-clinical validation of hardware (a display), not a machine learning model requiring a training set.

9. How the Ground Truth for the Training Set Was Established

Not applicable. (See #8)

Ask a specific question about this device

The Philips IntelliSite Pathology Solution (PIPS) is an automated digital slide creation, viewing and management, system. The PIPS is intended for in vitro diagnostic use as an aid to the pathologist to review and interpret digital images of surgical pathology slides prepared from formalin-fixed paraffin embedded (FFPE) tissue. The PIPS is not intended for use with frozen section, cytology, or non-FFPE hematopathology specimens.

The PIPS comprises the Image Management System (IMS) the Ultra Fast Scanner (UFS) and Philips PP27QHD display or a Beacon C411W display. The PIPS is for creation and viewing of digital images of scanned glass slides that would otherwise be appropriate for manual visualization by conventional light microscopy. It is the responsibility of a qualified pathologist to employ appropriate procedures and safeguards to assure the interpretation of images obtained using PIPS.

The Philips IntelliSite Pathology Solution (PIPS) is an automated digital slide creation, viewing and management, system. The PIPS comprises the Image Management System (IMS) the Ultra Fast Scanner (UFS) and Philips PP27QHD display or a Beacon C411W display.

Ask a specific question about this device

The Philips IntelliSite Pathology Solution (PIPS) 5.1 is an automated digital slide creation, viewing, and management system. The PIPS 5.1 is intended for in vitro diagnostic use as an aid to the pathologist to review and interpret digital images of surgical pathology slides prepared from formalin-fixed paraffin embedded (FFPE) tissue. The PIPS 5.1 is not intended for use with frozen section, cytology, or non-FFPE hematopathology specimens.

The PIPS 5.1 comprises the Imagement System (IMS) 4.2, Ultra Fast Scanner (UFS), Pathology Scanner SG20, Pathology Scanner SG60, Pathology Scanner SG300 and PP27QHD Display. The PIPS 5.1 is for creation and viewing of digital images of scanned glass slides that would otherwise be appropriate for manual visualization by conventional light microscopy. It is the responsibility of a qualified pathologist to employ appropriate procedures and safeguards to assure the validity of the interpretation of images obtained using PIPS 5.1.

The Philips IntelliSite Pathology Solution (PIPS) 5.1 is an automated digital slide creation, viewing, and management system. PIPS 5.1 consists of two subsystems and a display component:

1. Subsystems:
   a. A scanner in any combination of the following scanner models
   i. Ultra Fast Scanner (UFS)
   ii. Pathology Scanner SG with different versions for varying slide capacity Pathology Scanner SG20, Pathology Scanner SG60, Pathology Scanner SG300
   b. Image Management System (IMS) 4.2
2. Display PP27QHD

Here's a breakdown of the acceptance criteria and study details for the Philips IntelliSite Pathology Solution 5.1, based on the provided FDA 510(k) summary:

Acceptance Criteria and Reported Device Performance

Study Details

2. Sample sized used for the test set and the data provenance:

• Non-Clinical (Pixelwise Comparison):

  • Sample Size: 42 FFPE tissue glass slides from different anatomic locations. Three regions of interest (ROI) were selected from each scanned image.
  • Data Provenance: Not explicitly stated, but likely retrospective from existing archives given the nature of image comparison. The country of origin is not specified.

• Precision Study:

  • Sample Size: Not explicitly stated as a single number but implied by the "Number of Comparison Pairs" in the tables:
    • Intra-system: 3600 comparison pairs (likely 3 scanners with multiple reads/slides contributing).
    • Inter-system: 3610 comparison pairs.
    • Inter-site: 1228 comparison pairs.
  • Data Provenance: Not explicitly stated, but the inter-site component suggests data from multiple locations. Retrospective or prospective is not specified.

• Clinical Study:

  • Sample Size: 952 cases consisting of multiple organ and tissue types.
  • Data Provenance: Cases were divided over three sites. Retrospective or prospective is not specified, but the design (randomized order, washout period) suggests a prospective setup for the reading phase. The "original sign-out diagnosis rendered at the institution" implies a retrospective component for establishing the initial ground truth.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

• Non-Clinical (Pixelwise Comparison): No experts were explicitly mentioned for ground truth establishment; the comparison was purely technical (pixel-to-pixel).
• Precision Study: The ground truth for agreement was based on the comparison of diagnoses by pathologists, but the initial "ground truth" for the slides themselves (e.g., what they actually represented) isn't detailed in terms of expert consensus.
• Clinical Study:
  • Initial Ground Truth: The "original sign-out diagnosis rendered at the institution, using an optical (light) microscope" served as the primary reference diagnosis. The qualifications of these original pathologists are implied to be standard for their role but not explicitly stated (e.g., "radiologist with 10 years of experience").
  • Adjudication: Three adjudicators reviewed the reader diagnoses against the sign-out diagnosis to determine concordance, minor discordance, or major discordance. Their qualifications are not specified beyond being "adjudicators."

4. Adjudication method (for the test set):

• Clinical Study: Three adjudicators reviewed the reader diagnoses (from both manual digital and manual optical modalities) against the original sign-out diagnosis. The method for resolving disagreements among the three adjudicators (e.g., 2+1 majority, consensus) is not specified.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

• Yes, a MRMC study was done, but it was for comparative non-inferiority between digital and optical methods by human readers, not explicitly for AI assistance. The study compared human pathologists reading slides using the digital system (PIPS 5.1) versus human pathologists reading slides using a traditional optical microscope.
• Effect Size of AI: This study does not involve AI assistance for human readers. The device (PIPS 5.1) is a whole slide imaging system, not an AI diagnostic tool. Therefore, there is no reported effect size regarding human reader improvement with AI assistance from this study.

6. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done:

• No. The Philips IntelliSite Pathology Solution 5.1 is described as "an aid to the pathologist to review and interpret digital images." The clinical study clearly focuses on the performance of human pathologists using the system, demonstrating its non-inferiority to optical microscopy for human interpretation. There is no mention of a standalone algorithm performance.

7. The type of ground truth used:

• Non-Clinical (Pixelwise Comparison): The "ground truth" was the direct pixel data from the predicate device, against which the subject device's reproduced pixels were compared for identity.
• Precision Study: The ground truth for evaluating agreement rates was the diagnoses made by pathologists on different scans of the same slides. The ultimate truth of the disease state was implicitly tied to the original diagnostic process.
• Clinical Study: The primary ground truth was "the original sign-out diagnosis rendered at the institution, using an optical (light) microscope." This represents a form of expert consensus/established diagnosis within a clinical setting.

8. The sample size for the training set:

• Not Applicable / Not Provided. The provided document describes a 510(k) submission for a Whole Slide Imaging (WSI) system, which is a medical device for generating, viewing, and managing digital images of pathology slides. It acts as a digital microscope. It is not an AI algorithm or a diagnostic tool that requires a training set in the typical machine learning sense to learn a particular diagnostic task. Therefore, no training set data is relevant or provided here.

9. How the ground truth for the training set was established:

• Not Applicable / Not Provided. As explained above, this device does not utilize a training set in the AI/ML context.

Ask a specific question about this device

The Philips IntelliSite Pathology Solution (PIPS) is an automated digital side creation, viewing, and management system. The PIPS is intended for in vitro diagnostic use as an aid to the pathologist to review and interpret digital images of surgical pathology slides prepared from formalin-fixed paraffin embedded (FFPE) tissue. The PIPS is not intended for use with frozen section, cytology, or non-FFPE hematopathology specimens.

The PIPS comprises the Image Management System (IMS), the Ultra Fast Scanner (UFS) and Display. The PIPS is for creation and viewing of digital images of scanned glass slides that would otherwise be appropriate for manual visualization by conventional light microscopy. It is the responsibility of a qualified pathologist to employ appropriate procedures and safeguards to assure the validity of the interpretation of images obtained using PIPS.

Philips IntelliSite Pathology Solution (PIPS) is an automated digital slide creation, viewing, and management system. PIPS consists of two subsystems and a display component:

• . Ultra Fast Scanner (UFS)
• Image Management System (IMS)
• Display

This document does not contain the information requested for acceptance criteria and a study proving device performance as it is a 510(k) summary for a modified device (K203845) that claims substantial equivalence to a predicate device (K192259) without requiring new clinical performance data.

The key reason for not needing a new clinical performance study is explicitly stated: "The subject device with the modified IMS subsystem did not require clinical performance data to demonstrate substantial equivalence to the currently marketed predicate device, as image quality was not impacted by the introduced change."

Instead of a new clinical study, the document describes non-clinical verification testing to support the substantial equivalence claim. This included:

• A pixel comparison test to determine pixel equivalence.
• Testing of requirements, risk control measures, integration, and regression.

Therefore, since no new clinical study was conducted for this specific 510(k), I cannot provide the requested information about acceptance criteria, sample sizes, expert involvement, adjudication, MRMC studies, standalone performance, or ground truth establishment for a clinical performance study. The information provided relates to the non-clinical verification of a software change impacting rendering, not a full clinical validation of the device's diagnostic performance for its intended use.

Ask a specific question about this device

The Philips IntelliSite Pathology Solution (PIPS) is an automated digital slide creation, viewing, and management system. The PIPS is intended for in vitro diagnostic use as an aid to the pathologist to review and interpret digital images of surgical pathology slides prepared from formalin-fixed paraffin embedded (FFPE) tissue. The PIPS is not intended for use with frozen section, cytology, or non-FFPE hematopathology specimens.

The PIPS comprises the Image Management System (IMS), the Ultra Fast Scanner (UFS) and display. The PIPS is for creation and viewing of digital images of scanned glass slides that would otherwise be appropriate for manual visualization by conventional light microscopy. It is the responsibility of a qualified pathologist to employ appropriate procedures and safeguards to assure the validity of the interpretation of images obtained using PIPS.

Philips IntelliSite Pathology Solution (PIPS) is an automated digital slide creation, viewing, and management system. PIPS consists of two sub-systems and a display component:

• . Image Management System (IMS)
• Ultra Fast Scanner (UFS)
• . Display

The provided document is a 510(k) Summary for a minor modification to an existing device, the Philips IntelliSite Pathology Solution (PIPS). The modification is a new display panel. Therefore, the information primarily focuses on demonstrating that this new panel does not adversely affect the device's performance compared to the predicate device.

Here's the breakdown of the requested information based on the provided text:

1. A table of acceptance criteria and the reported device performance

The document does not explicitly state "acceptance criteria" in the format of a table with specific numerical thresholds for performance. Instead, it refers to compliance with international and FDA-recognized consensus standards and verification tests. The "reported device performance" is framed as demonstrating similarity to the predicate device and compliance with these standards.

2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

The document primarily describes non-clinical performance testing of a new display panel. It does not mention a "test set" in the context of patient data or clinical imaging for diagnostic performance evaluation. The tests performed were on the display itself.

• No information on sample size for a test set of patient data.
• No information on data provenance (country of origin, retrospective/prospective).
• The tests were performed on the hardware (display panel).

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

This information is not applicable. The study described is not a clinical study on diagnostic accuracy or interpretation where expert ground truth would be established. It is a non-clinical study verifying the technical performance of a hardware component (display).

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

This information is not applicable for the same reason as point 3.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

No MRMC comparative effectiveness study was done. The device (Philips IntelliSite Pathology Solution) is a whole slide imaging system, not an AI-assisted diagnostic tool. This submission is for a hardware change (display panel) to an existing cleared device. The document explicitly states: "The proposed device with the new display panel did not require clinical performance data since substantial equivalence to the currently marketed predicate device was demonstrated with the following attributes: - Intended Use / Indications for Use, - Technological characteristics, - Non-clinical performance testing, and - Safety and effectiveness." Therefore, no improvement with AI assistance was measured or is relevant to this specific submission.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

This is not applicable. The device is a whole slide imaging system, not an algorithm, and this submission concerns a display hardware change.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

This is not applicable as there was no clinical study involving patient data or diagnostic interpretation for which ground truth would be established. The "ground truth" for the non-clinical tests would be the established technical specifications and performance limits for display devices.

8. The sample size for the training set

This is not applicable. The device is a whole slide imaging system, not an AI/ML algorithm that requires a "training set."

9. How the ground truth for the training set was established

This is not applicable for the same reason as point 8.

Ask a specific question about this device

The Philips IntelliSite Pathology Solution (PIPS) is an automated digital siide creation, viewing, and management system. The PIPS is intended for in vitro diagnostic use as an aid to the pathologist to review and interpret digital images of surgical pathology slides prepared from formalin-fixed paraffin embedded (FFPE) tissue. The PIPS is not intended for use with frozen section, cytology, or non-FFPE hematopathology specimens.

The PIPS comprises the Image Management System (IMS), the Ultra Fast Scanner (UFS) and Display. The PIPS is for creation and viewing of digital images of scanned glass slides that would otherwise be appropriate for manual visualization by conventional light microscopy. It is the responsibility of a qualified pathologist to employ appropriate procedures and safeguards to assure the validity of the interpretation of images obtained using PIPS.

The Philips IntelliSite Pathology Solution (PIPS) is an automated digital slide creation, viewing, and management system. The PIPS consists of two sub-systems and a Display component:

• Image Management System (IMS)
• Ultra Fast Scanner (UFS)
• Display

PIPS 2.6.1 introduces one major change compared to the predicate device PIPS 2.5:

• New display PP27QHD

This document is a 510(k) summary for the Philips IntelliSite Pathology Solution (PIPS) 2.6.1, which introduces a new display (PP27QHD) to the system. The submission claims substantial equivalence to the predicate device, PIPS 2.5, and focuses on demonstrating that the new display does not alter the safety or effectiveness of the overall system. Therefore, the study details provided are primarily related to non-clinical verification and validation of the display, rather than a clinical study evaluating diagnostic performance.

Here's a breakdown of the requested information based on the provided text:

1. Table of Acceptance Criteria and Reported Device Performance

The document does not explicitly present a table of acceptance criteria for diagnostic performance or specific clinical metrics. Instead, it focuses on demonstrating that the new display (PP27QHD) maintains the same technological characteristics and performance as the predicate display (PS27QHDCR) with respect to image quality and calibration.

2. Sample Size Used for the Test Set and Data Provenance

The document does not describe a clinical test set in the traditional sense for diagnostic performance. The "test set" for the PIPS 2.6.1, as described, appears to be related to non-clinical verification and in-house validation with user representatives.

• Sample Size for Test Set: Not explicitly stated in terms of number of cases or images. For the "in-house validation with user representatives," it mentions "Each user was provided a Design Validation Survey," implying a number of users, but the exact count is not given.
• Data Provenance: Not applicable as a clinical study with patient data was not conducted. The testing described is primarily technical and user experience validation of a hardware change.

3. Number of Experts Used to Establish Ground Truth and Qualifications

This information is not applicable to the documented study for PIPS 2.6.1. The study focuses on technical and user validation of a display change, not diagnostic performance where expert ground truth for specific cases would be established. For the "in-house validation with user representatives," these are described as "users" but their specific qualifications (e.g., pathologists with x years of experience) are not detailed, nor are they establishing ground truth for diagnostic purposes.

4. Adjudication Method for the Test Set

Not applicable. There was no clinical test set requiring adjudication of diagnostic interpretations. The "in-house validation" used a "Design Validation Survey" for user feedback, which is a different type of assessment.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was Done, and Effect Size

No, an MRMC comparative effectiveness study was not explicitly stated or described. The document explicitly states: "PIPS 2.6.1 did not require clinical studies to establish substantial equivalence to the predicate device PIPS 2.5." The focus was on demonstrating that the display change did not negatively impact the system's performance, eliminating the need for a new clinical study. Therefore, there is no reported effect size for human readers with vs. without AI assistance. The Philips IntelliSite Pathology Solution is a Whole Slide Imaging (WSI) system for pathologists to review digital images, and the AI component (if any beyond image processing) is not the focus of this 510(k).

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was Done

Not applicable. The Philips IntelliSite Pathology Solution, including the new display, is explicitly described as "an aid to the pathologist to review and interpret digital images." It is a system designed for human-in-the-loop interpretation, not a standalone diagnostic algorithm.

7. The Type of Ground Truth Used

Not applicable for a diagnostic performance study. The "ground truth" in this context would be compliance with technical specifications and user satisfaction/usability, rather than expert consensus on disease diagnosis or pathology.

8. The Sample Size for the Training Set

Not applicable. This 510(k) does not describe the development or training of an AI algorithm; it pertains to an update of a Whole Slide Imaging system, specifically a new display.

9. How the Ground Truth for the Training Set was Established

Not applicable, as no training set for an AI algorithm is described.

Ask a specific question about this device

The Philips IntelliSite Pathology Solution (PIPS) is an automated digital slide creation, viewing, and management system. The PIPS is intended for in vitro diagnostic use as an aid to the pathologist to review and interpret digital images of surgical pathology slides prepared from formalin-fixed paraffin embedded (FFPE) tissue. The PIPS is not intended for use with frozen section, cytology, or non-FFPE hematopathology specimens.

The PIPS comprises the Image Management System (IMS), the Ultra Fast Scanner (UFS) and Display. The PIPS is for creation and viewing of digital images of scanned glass slides that would otherwise be appropriate for manual visualization by conventional light microscopy. It is the responsibility of a qualified pathologist to employ appropriate procedures and safeguards to assure the validity of the interpretation of images obtained using PIPS.

The Philips IntelliSite Pathology Solution (PIPS) is an automated digital slide creation, management, viewing and analysis system.

The PIPS consists of two subsystems and a display:

• Ultra Fast Scanner (UFS) (for software UFS1.7.1.1); ●
• Image Management System (IMS) (for software IMS2.5.1.1); ●
• . Display (PS27QHDCR).

The UFS consists of optical, mechanical, electronic and software elements to scan FFPE tissue mounted on glass slides at a resolution of 0.25 um per pixel, which is equivalent to a 40x objective, to create digital Whole Slide Images (WSI). The UFS has a capacity of 300 slides (15 glass slide racks with up to 20 slides per rack). After the slide racks are loaded into the UFS, the UFS automatically detects and starts scanning the slides. CCD cameras are used to capture color images from the back-lit tissue specimen. An LED light source employs toplit illumination to capture the barcode and back-lit illumination for tissue scanning. The stage (STG) and Image Capturing Unit (ICU) are fixed to each other and to the base frame to ensure correct positioning of the slide and to suppress external disturbances. Proprietary software is used for image processing during acquisition. Philips' proprietary format, iSyntax, is used to store and transmit the images between the UFS and the IMS.

The IMS is a software only subsystem to be used with the Display. Functionality of the IMS includes the ability to view images, organize workload, and annotate and bookmark scanned images. The user manual for PIPs specifies compatible computer environment hardware and software that is not included as part of the system.

The different subsystems of the PIPS are connected over an IT network at the user site. The IT hardware/software that supports the IMS Application Server & Storage software is not provided as part of the PIPS, but may be located in a central server room separate from the workstation with the IMS viewing software and Display. The communication of data between UFS and IMS is via a customer provided wired network or a direct connected cable between these subsystems. PIPS includes a display that has been validated as part of the pivotal clinical study.

The PIPS allows pathologists to view and evaluate digital images of formalin-fixed, paraffinembedded (FFPE) tissue slides that would otherwise be appropriate for manual visualization by conventional brightfield (light) microscopy. The PIPS does not include any automated Image Analysis Applications that would constitute computer aided detection or diagnosis.

The provided text describes the regulatory acceptance criteria and supporting studies for the Philips IntelliSite Pathology Solution (PIPS), a digital whole slide imaging (WSI) system for pathology.

Here's an breakdown of the requested information:

1. Table of Acceptance Criteria and Reported Device Performance

The regulatory document outlines specific performance characteristics that the PIPS device must meet, primarily focusing on showing non-inferiority to traditional optical microscopy for diagnostic purposes and demonstrating precision and reproducibility.

Ask a specific question about this device